| DC Field | Value | Language |
|---|
| dc.contributor.author | Avdeeva, N. V. | - |
| dc.contributor.author | Pokrovskiy, M. V. | - |
| dc.contributor.author | Zhernakova, N. I. | - |
| dc.contributor.author | Artyushkova, E. B. | - |
| dc.date.accessioned | 2020-05-18T19:25:51Z | - |
| dc.date.available | 2020-05-18T19:25:51Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.citation | The definition of specific antiparkinsonian effects of Rapitalam / N. V. Avdeeva, M. V. Pokrovskiy, N. I. Zhernakova [et al.] // Journal of International Pharmaceutical Research. - 2018. - Vol.45.- P. 430-434. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/30062 | - |
| dc.description.abstract | Previously, we identified a metabotropic glutamate receptor 4 (mGluR4) as a potential target for drugs and predicted that activation of mGluR4 could provide a palliative advantage in the treatment of Parkinson's disease. Determine the mechanism of action of Rapitalam in vitro on a cell culture with mGluR4 over expression. The HEK293T cell line expressing human mGluR4 was used in the work | ru |
| dc.language.iso | en | ru |
| dc.subject | medical | ru |
| dc.subject | pharmacy | ru |
| dc.subject | Parkinson's disease | ru |
| dc.subject | Rapitalam | ru |
| dc.subject | metabotropic glutamate receptor | ru |
| dc.title | The definition of specific antiparkinsonian effects of Rapitalam | ru |
| dc.type | Article | ru |
| Appears in Collections: | Статьи из периодических изданий и сборников (на иностранных языках) = Articles from periodicals and collections (in foreign languages)
|
